Press Releases

GWOXI's primary goal is to strive for a new drug launch in the shortest possible time by getting the product to market through conditional approval. Simultaneously, it's pushing for its production lines to pass formal GMP certification, which will allow for official product manufacturing. This will also help the company further expand its capabilities and capacity in cell therapy CDMO.

A leading domestic stem cell biotech company, GWOXI Stem Cell, announced that its stable expansion technology for induced pluripotent stem cells (iPSCs) has officially been granted a Taiwan invention patent. This patent further strengthens the company's overall portfolio for the industrial and technological development of iPSCs in Taiwan.

The new stem cell drug for stroke, "Si Yi You," developed in collaboration between Hualien Tzu Chi Hospital and GWOXI Stem Cell, is expected to become a new hope for stroke patients. GWOXI Stem Cell recently received a letter of consent for review from the Ministry of Health and Welfare (MOHW), and will now begin to launch a Phase III clinical trial and apply for a temporary drug license.

GWOXI Stem Cell recently announced that its new stem cell drug for stroke (Si Yi You GXNPC1) has completed its Phase II clinical trial report. The company has obtained a letter of consent for review from the Ministry of Health and Welfare (MOHW) and will simultaneously proceed with its Phase III clinical trial application and a request for a temporary drug license.

GWOXI Stem Cell announced that its new cell drug for osteoarthritis has been submitted to the Taiwan Food and Drug Administration (TFDA) for a Phase III clinical trial application. In August, the company also secured a Taiwan invention patent for a pharmaceutical composition to treat osteoarthritis, which will help accelerate its commercialization timeline.

GWOXI Stem Cell today announced that, through an innovative industry–academia collaboration model, it has been granted a Taiwan invention patent for “pharmaceutical compositions comprising extracellular vesicles isolated from adipose tissue and biologics, and their use in the treatment of arthritis.” This represents a breakthrough development in the treatment of rheumatoid arthritis.

GWOXI Stem Cell announced today that it has been granted an invention patent for the use of highly phenotypic mesenchymal stem cells in the treatment of frontotemporal dementia, Alzheimer’s disease, and amyloidosis-related disorders. This innovation is expected to advance the development of therapies for rare diseases and may become one of the treatment options for patients with Alzheimer’s disease in the future.

GWOXI Stem Cell announced that it has been granted a Japanese invention patent for the use of stem cell therapeutics in treating arthritis and the method for preparing such stem cell therapeutics. Experiments have demonstrated that this patented approach is more effective than traditional 2D-cultured stem cells in slowing the progression of degenerative arthritis.

GWOXI Stem Cell announced today that it has been granted two Taiwan invention patents for a pharmaceutical composition for the treatment of chronic stroke. These patents help to complete the overall patent portfolio for GWOXI’s stroke stem cell therapeutics and are expected to facilitate future licensing negotiations, accelerating the commercialization timeline.

GWOXI Stem Cell today received the “2023 Hsinchu Science Park Innovative Product Award” from the National Science and Technology Council, Hsinchu Science Park Administration, in recognition of its innovative R&D capabilities, product commercialization expertise, and contributions to advancing disease treatment applications.